# Supplement: Adjuvant Screening for an inactivated SFTSV Vaccine

> **NIH NIH N01** · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · 2022 · $500,000

## Abstract

The objective of the contract is to identify novel adjuvants, as part of the NIAID Vaccine Adjuvant Discovery Program and the contractor has developed a portfolio of novel compounds. As part of HHS’ effort to advance the development of vaccines against tick-borne pathogens, the contractor will conduct a formal comparison of adjuvants for a vaccine against severe fever with thrombocytopenia syndrome virus (SFTSV). No such vaccine is currently available, and the contractor has a model system in which the efficacy of such vaccines can be evaluated. SFTS was first reported in 2009 and has since been spreading. It has a fatality rate in humans, an accidental host, of up to 30% and is transmitted not only by ticks, but can also be spread from person to person. In this project, beta-propiolactone-inactivated virus will be formulated with three experimental adjuvants (in comparison to Alum and Addavax) and the efficacy of the vaccines will be evaluated.

## Key facts

- **NIH application ID:** 10672558
- **Project number:** 75N93019C00046-P00007-9999-2
- **Recipient organization:** ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
- **Principal Investigator:** ADOLFO GARCIA-SASTRE
- **Activity code:** N01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $500,000
- **Award type:** —
- **Project period:** 2019-09-30 → 2024-09-29

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10672558

## Citation

> US National Institutes of Health, RePORTER application 10672558, Supplement: Adjuvant Screening for an inactivated SFTSV Vaccine (75N93019C00046-P00007-9999-2). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10672558. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*